Metabolic therapy in the comprehensive treatment of patients with comorbidity of chronic pancreatitis and stable coronary artery disease

Metabolic therapy is one of the few ways to restore normal functions of all the vital organs and systems. The goal of the research was to explore the effectiveness of a course of treatment using metabolic drug Vazonat (meldonium dihydrate) to correct prooxidant-antioxidant and trophological disorders in patients with comorbid course of chronic pancreatitis (CP) and stable coronary artery disease (SCAD). The study included 90 patients with CP in combination with SCAD, who were divided into two groups (depending on the treatment program): I group (45 patients) received conventional treatment (CT); group II (45 patients) in addition to CT received Vazonat as follows: 5 ml intravenous bolus injection 1 time a day for 10 days followed by administration of 1 capsule (250 mg), 2 times per day for one month. It has been shown that the addition of Vazonat to the treatment of patients with comorbidity of CP and SCAD is more conducive to improving the performance and trophological prooxidant-antioxidant status than the standard basic therapy.